Archive Newsletter

61. 03.19.25 -- Mesenchymal Stem Cells Hold The Key To Treating Degenerative Conditions 3/19/2025
    03/19/25 Cell & Gene Newsletter
62. 03.18.25 -- Exploring The Benefits Of Novel Nucleases In CRISPR Therapies 3/18/2025

    03/18/25 Cell & Gene Newsletter

63. 03.18.25 -- STREAM Edition: Keys To A Successful cGMP Manufacturing Operation Delivering CGTs 3/18/2025
    03/18/25 Cell & Gene Newsletter
64. 03.18.25 -- Understanding The New U.K. MHRA 'Draft Guideline On Individualised mRNA Cancer Immunotherapies' 3/18/2025
    03/18/25 Cell & Gene Newsletter
65. 03.17.25 -- Promote Successful Cell Growth And Viability From Start-Up To Scale-Up 3/17/2025
    03/17/25 Cell & Gene Newsletter
66. 03.17.25 -- February 2025 — CDMO Opportunities And Threats Report 3/17/2025
    03/17/25 Cell & Gene Newsletter
67. 03.14.25 -- Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases 3/14/2025
    03/14/25 Cell & Gene Newsletter
68. 03.13.25 -- Agile Functional Support To Accelerate Your Novel Therapies 3/13/2025

    03/13/25 Cell & Gene Newsletter

69. 03.13.25 -- Distributed Cell Therapy Manufacturing Trade-Offs You Should Know About 3/13/2025
    03/13/25 Cell & Gene Newsletter
70. 03.12.25 -- Will 2025 Represent A Continuation Of FDA's 2024 Developments? 3/12/2025
    03/12/25 Cell & Gene Newsletter